179 related articles for article (PubMed ID: 26323873)
1. Synthesis and anti-cancer potential of the positional isomers of NOSH-aspirin (NBS-1120) a dual nitric oxide and hydrogen sulfide releasing hybrid.
Vannini F; MacKessack-Leitch AC; Eschbach EK; Chattopadhyay M; Kodela R; Kashfi K
Bioorg Med Chem Lett; 2015 Oct; 25(20):4677-82. PubMed ID: 26323873
[TBL] [Abstract][Full Text] [Related]
2. Positional isomerism markedly affects the growth inhibition of colon cancer cells by NOSH-aspirin: COX inhibition and modeling.
Vannini F; Chattopadhyay M; Kodela R; Rao PPN; Kashfi K
Redox Biol; 2015 Dec; 6():318-325. PubMed ID: 26319435
[TBL] [Abstract][Full Text] [Related]
3. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model.
Chattopadhyay M; Kodela R; Olson KR; Kashfi K
Biochem Biophys Res Commun; 2012 Mar; 419(3):523-8. PubMed ID: 22366248
[TBL] [Abstract][Full Text] [Related]
4. NOSH-Aspirin Inhibits Colon Cancer Cell Growth: Effects Of Positional Isomerism.
Vannini F; Kodela R; Chattopadhyay M; Kashfi K
Redox Biol; 2015 Aug; 5():421. PubMed ID: 28162291
[TBL] [Abstract][Full Text] [Related]
5. NOSH-aspirin (NBS-1120) inhibits pancreatic cancer cell growth in a xenograft mouse model: Modulation of FoxM1, p53, NF-κB, iNOS, caspase-3 and ROS.
Chattopadhyay M; Kodela R; Santiago G; Le TTC; Nath N; Kashfi K
Biochem Pharmacol; 2020 Jun; 176():113857. PubMed ID: 32061771
[TBL] [Abstract][Full Text] [Related]
6. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid has enhanced chemo-preventive properties compared to aspirin, is gastrointestinal safe with all the classic therapeutic indications.
Kodela R; Chattopadhyay M; Velázquez-Martínez CA; Kashfi K
Biochem Pharmacol; 2015 Dec; 98(4):564-72. PubMed ID: 26394025
[TBL] [Abstract][Full Text] [Related]
7. Utility Of Nitric Oxide And Hydrogen Sulfide-Releasing Chimeras As Anticancer Agents.
Kashfi K
Redox Biol; 2015 Aug; 5():420. PubMed ID: 28162289
[TBL] [Abstract][Full Text] [Related]
8. NOSH-aspirin (NBS-1120), a novel nitric oxide and hydrogen sulfide releasing hybrid, attenuates neuroinflammation induced by microglial and astrocytic activation: a new candidate for treatment of neurodegenerative disorders.
Lee M; McGeer E; Kodela R; Kashfi K; McGeer PL
Glia; 2013 Oct; 61(10):1724-34. PubMed ID: 23918470
[TBL] [Abstract][Full Text] [Related]
9. Exploring the Potential of Nitric Oxide and Hydrogen Sulfide (NOSH)-Releasing Synthetic Compounds as Novel Priming Agents against Drought Stress in
Antoniou C; Xenofontos R; Chatzimichail G; Christou A; Kashfi K; Fotopoulos V
Biomolecules; 2020 Jan; 10(1):. PubMed ID: 31936819
[TBL] [Abstract][Full Text] [Related]
10. Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo.
Kashfi K; Borgo S; Williams JL; Chen J; Gao J; Glekas A; Benedini F; Del Soldato P; Rigas B
J Pharmacol Exp Ther; 2005 Mar; 312(3):978-88. PubMed ID: 15528453
[TBL] [Abstract][Full Text] [Related]
11. NOSH-sulindac (AVT-18A) is a novel nitric oxide- and hydrogen sulfide-releasing hybrid that is gastrointestinal safe and has potent anti-inflammatory, analgesic, antipyretic, anti-platelet, and anti-cancer properties.
Kashfi K; Chattopadhyay M; Kodela R
Redox Biol; 2015 Dec; 6():287-296. PubMed ID: 26298203
[TBL] [Abstract][Full Text] [Related]
12. Hydrogen sulfide-releasing aspirin suppresses NF-κB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo.
Chattopadhyay M; Kodela R; Nath N; Barsegian A; Boring D; Kashfi K
Biochem Pharmacol; 2012 Mar; 83(6):723-32. PubMed ID: 22209867
[TBL] [Abstract][Full Text] [Related]
13. NOSH-aspirin (NBS-1120), a dual nitric oxide and hydrogen sulfide-releasing hybrid, reduces inflammatory pain.
Fonseca MD; Cunha FQ; Kashfi K; Cunha TM
Pharmacol Res Perspect; 2015 Jun; 3(3):e00133. PubMed ID: 26236481
[TBL] [Abstract][Full Text] [Related]
14. NOSH-Aspirin: A Novel Nitric Oxide-Hydrogen Sulfide-Releasing Hybrid: A New Class of Anti-inflammatory Pharmaceuticals.
Kodela R; Chattopadhyay M; Kashfi K
ACS Med Chem Lett; 2012 Mar; 3(3):257-262. PubMed ID: 22916316
[TBL] [Abstract][Full Text] [Related]
15. The mechanism of action of nitric oxide-donating aspirin.
Kashfi K; Rigas B
Biochem Biophys Res Commun; 2007 Jul; 358(4):1096-101. PubMed ID: 17512900
[TBL] [Abstract][Full Text] [Related]
16. Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: a general property and evidence of a tissue type-independent effect.
Chattopadhyay M; Kodela R; Nath N; Dastagirzada YM; Velázquez-Martínez CA; Boring D; Kashfi K
Biochem Pharmacol; 2012 Mar; 83(6):715-22. PubMed ID: 22222427
[TBL] [Abstract][Full Text] [Related]
17. New nitric oxide or hydrogen sulfide releasing aspirins.
Lazzarato L; Chegaev K; Marini E; Rolando B; Borretto E; Guglielmo S; Joseph S; Di Stilo A; Fruttero R; Gasco A
J Med Chem; 2011 Aug; 54(15):5478-84. PubMed ID: 21688846
[TBL] [Abstract][Full Text] [Related]
18. The differential cell signaling effects of two positional isomers of the anticancer NO-donating aspirin.
Hua A; Mackenzie GG; Rigas B
Int J Oncol; 2009 Oct; 35(4):837-44. PubMed ID: 19724920
[TBL] [Abstract][Full Text] [Related]
19. Positional isomers of aspirin are equally potent in inhibiting colon cancer cell growth: differences in mode of cyclooxygenase inhibition.
Kodela R; Chattopadhyay M; Goswami S; Gan ZY; Rao PP; Nia KV; Velázquez-Martínez CA; Kashfi K
J Pharmacol Exp Ther; 2013 Apr; 345(1):85-94. PubMed ID: 23349335
[TBL] [Abstract][Full Text] [Related]
20. Reconsidering the Role of Cyclooxygenase Inhibition in the Chemotherapeutic Value of NO-Releasing Aspirins for Lung Cancer.
Martin-Martin A; Rivera-Dictter A; Muñoz-Uribe M; López-Contreras F; Pérez-Laines J; Molina-Berríos A; López-Muñoz R
Molecules; 2019 May; 24(10):. PubMed ID: 31109107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
